State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, China.
State Key Laboratory of Quality Research in Chinese Medicines, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, 999078, China.
Int J Biol Sci. 2023 Jul 9;19(11):3499-3525. doi: 10.7150/ijbs.77720. eCollection 2023.
Combination therapy against cancer has gained increasing attention because it can help to target multiple pathways to tackle oncologic progression and improve the limited antitumor effect of single-agent therapy. Chinese medicine has been studied extensively in cancer therapy and proven to be efficacious in many cases due to its wide spectrum of anticancer activities. In this review, we aim to summarize the recent progress of active ingredients from Chinese medicine (AIFCM) in combination with various cancer therapeutic modalities, including chemotherapy, gene therapy, radiotherapy, phototherapy and immunotherapy. In addition to highlighting the potential contribution of AIFCM in combination cancer therapy, we also elucidate the underlying mechanisms behind their synergistic effect and improved anticancer efficacy, thereby encouraging the inclusion of these AIFCM as part of effective armamentarium in fighting intractable cancers. Finally, we present the challenges and future perspectives of AIFCM combination therapy as a feasible and promising strategy for the optimization of cancer treatment and better clinical outcomes.
联合疗法治疗癌症越来越受到关注,因为它可以帮助针对多种途径来解决肿瘤进展,并提高单一药物治疗的有限抗肿瘤效果。中药在癌症治疗中得到了广泛的研究,并因其广泛的抗癌活性在许多情况下被证明是有效的。在这篇综述中,我们旨在总结中药活性成分(AIFCM)与各种癌症治疗方式相结合的最新进展,包括化疗、基因治疗、放疗、光疗和免疫治疗。除了强调 AIFCM 在联合癌症治疗中的潜在贡献外,我们还阐明了它们协同作用和提高抗癌疗效的潜在机制,从而鼓励将这些 AIFCM 作为有效治疗手段的一部分,用于治疗难治性癌症。最后,我们提出了 AIFCM 联合治疗作为优化癌症治疗和改善临床结果的可行和有前途的策略所面临的挑战和未来展望。
Int J Biol Sci. 2023
J Ethnopharmacol. 2021-4-24
Front Bioeng Biotechnol. 2025-5-15
Int J Mol Sci. 2025-4-17
Cell Death Dis. 2024-12-24
Int J Biol Sci. 2024
Drug Des Devel Ther. 2024
Life (Basel). 2022-6-15
Acta Pharm Sin B. 2022-3
Evid Based Complement Alternat Med. 2022-3-17
Theranostics. 2022